Long, Georgina V.

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., et al. (2022) · Nature Medicine

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 256

Learning from clinical trials of neoadjuvant checkpoint blockade

Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 234

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J.-E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., et al. (2019) · Nature Medicine

Cancer Immunotherapy and BiomarkersAutoimmune Neurological Disorders and Treatments

Cited by 176

Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors

Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 153

Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

Johansson, P. A., Brooks, K., Newell, F., Palmer, J. M., Wilmott, J. S., Pritchard, A. L., Broit, N., Wood, S., Carlino, M. S., Leonard, C., et al. (2020) · Nature Communications

Ocular Oncology and TreatmentsCancer Genomics and Diagnostics

Cited by 153

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 151

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Lipson, E. J., Tawbi, H. A.-H., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P., Gogas, H., Lao, C. D., Janoski de Menezes, J., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 150

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling

Melanoma and MAPK PathwaysCancer Cells and Metastasis

Cited by 143

The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma

Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology

Cancer Immunotherapy and BiomarkersAdrenal Hormones and Disorders

Cited by 142

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

Lee, H., Quek, C., Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S. Y., Nur Gide, T., Shang, P., Attrill, G. H., et al. (2019) · OncoImmunology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 115

MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer

Cipponi, A., Goode, D. L., Bedo, J., McCabe, M. J., Pajic, M., Croucher, D. R., Rajal, A. G., Junankar, S. R., Saunders, D. N., Lobachevsky, P., et al. (2020) · Science

PI3K/AKT/mTOR signaling in cancerEvolution and Genetic Dynamics

Cited by 103

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

Syeda, M. M., Wiggins, J. M., Corless, B. C., Long, G. V., Flaherty, K. T., Schadendorf, D., Nathan, P. D., Robert, C., Ribas, A., Davies, M. A., et al. (2021) · The Lancet Oncology

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 101

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma

Long, G. V., Shklovskaya, E., Satgunaseelan, L., Mao, Y., da Silva, I. P., Perry, K. A., Diefenbach, R. J., Gide, T. N., Shivalingam, B., Buckland, M. E., et al. (2025) · Nature Medicine

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 83

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Garg, M., Couturier, D.-L., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., Jönsson, G. B., Newton-Bishop, J., Parkinson, C., et al. (2021) · Nature Communications

Cutaneous Melanoma Detection and ManagementBreast Cancer Treatment Studies

Cited by 70

Abstract CT001: a personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

Khattak, A., Carlino, M., Meniawy, T., Ansstas, G., Medina, T., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2023) · Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 51

Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.

Weber, J. S., Khattak, M. A., Carlino, M. S., Meniawy, T., Taylor, M. H., Ansstas, G., Kim, K. B., McKean, M., Sullivan, R. J., Faries, M. B., et al. (2024) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 45

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Tetzlaff, M. T., Adhikari, C., Lo, S., Rawson, R. V., Amaria, R. N., Menzies, A. M., Wilmott, J. S., Ferguson, P. M., Ross, M. I., Spillane, A. J., et al. (2020) · Annals of Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 37

Ipilimumab‐induced hypophysitis in melanoma patients: an Australian case series

Lam, T., Chan, M. M. K., Sweeting, A. N., De Sousa, S. M. C., Clements, A., Carlino, M. S., Long, G. V., Tonks, K., Chua, E., Kefford, R. F., et al. (2015) · Internal Medicine Journal

Cancer Immunotherapy and BiomarkersPituitary Gland Disorders and Treatments

Cited by 37

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients

Pirozyan, M. R., McGuire, H. M., Emran, A. A., Tseng, H.-Y., Tiffen, J. C., Lee, J. H., Carlino, M. S., Menzies, A. M., Long, G. V., Scolyer, R. A., et al. (2020) · Frontiers in Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 34

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

Rozeman, E. A., Menzies, A. M., Krijgsman, O., Hoefsmit, E. P., van de Wiel, B. A., Sikorska, K., Van, T. M., Eriksson, H., Bierman, C., Gonzalez, M., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 20

Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.

Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A. M., Lichinitser, M., Khattak, M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 14

Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.

Dearden, H. C., Au, L., Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Curvietto, M., Khoo, C., Atkinson, V., Lo, S., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2